Clinical Studies

STP705

Indication:

Situ squamous cell carcinoma (isSCC)

Progress:

Phase Ⅱb clinical trials in the U.S. & China

Primary endpoints:

Histological clearance of isSCC lesions as determined by central pathology review upon completion of treatment.

Indication:

Basal cell carcinoma

Progress:

Phase Ⅱ clinical trial

Primary endpoints:

Complete histological clearance of tumor cells.

Indication:

Keloid scar prevention

Progress:

Phase Ⅰ/Ⅱ clinical trial

Primary endpoints:

To measure the rate of recurrence in patients who have undergone keloidectomy surgery alone versus those who have undergone surgery plus administration of STP705 evaluated at three months, six months, and 12 months post-surgical excision.

Indication:

Facial Squamous Cell Skin Cancer In Situ

Progress:

Phase Ⅰ/Ⅱ clinical trial

Primary endpoints:

To determine the number of patients with histological clearance (HC) of facial isSCC lesions at the end of treatment with STP705.

Indication:

Liver Cancer (Basket)

Progress:

Phase I clinical trial

Primary endpoints:

To determine the maximum tolerated dose and to establish the recommended dose for future Phase Ⅱ clinical trials.

Indication:

Medical aesthetic treatment for fat sculpting

Progress:

Phase I clinical trial

Primary endpoints:

To assess injection comfort, characterize local and systemic safety, and evaluate histological changes of subcutaneous doses of STP705, and to compare the safety and tolerability of three different concentrations of STP705 to select dosages for future studies.

STP707

Indication:

Solid Tumors

Progress:

Phase I clinical trial

Primary endpoints:

To determine maximum tolerated dose and establish dosage recommendations for future Phase II studies.

Indication:

Primary Sclerosing Cholangitis

Progress:

Phase I clinical trial

Primary endpoints:

The safety, tolerability and pharmacokinetics of STP707

Combination Therapy

We are developing combination therapies with STP705 and immune checkpoint therapeutics for liver cancer.
We are also developing combination therapies with STP707 and immune checkpoint therapeutics for liver cancer, isSCC, and NSCLC.
We currently are collaborating with Innovent in the U.S. to explore the efficacy of STP705 plus sintilimab, a novel anti-PD-1 monoclonal antibody approved by the National Medical Products Administration (NMPA, formerly known as the China Food and Drug Administration) for use in the treatment of advanced cancers such as NSCLC.
We also are collaborating with Shanghai Junshi to conduct preclinical studies in the U.S. using STP705 plus Shanghai Junshi’s novel anti-PD-1 monoclonal antibody approved by the NMPA for use in treatment in advanced melanoma, squamous cell carcinoma and other indications.